SG11201607298QA - Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer - Google Patents
Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancerInfo
- Publication number
- SG11201607298QA SG11201607298QA SG11201607298QA SG11201607298QA SG11201607298QA SG 11201607298Q A SG11201607298Q A SG 11201607298QA SG 11201607298Q A SG11201607298Q A SG 11201607298QA SG 11201607298Q A SG11201607298Q A SG 11201607298QA SG 11201607298Q A SG11201607298Q A SG 11201607298QA
- Authority
- SG
- Singapore
- Prior art keywords
- eribulin
- cancer
- treatment
- combination therapy
- mtor inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947398P | 2014-03-03 | 2014-03-03 | |
| PCT/US2015/018335 WO2015134399A1 (en) | 2014-03-03 | 2015-03-02 | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607298QA true SG11201607298QA (en) | 2016-09-29 |
Family
ID=54055761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607298QA SG11201607298QA (en) | 2014-03-03 | 2015-03-02 | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
Country Status (11)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2949652B1 (en) | 2004-06-03 | 2019-08-07 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of halichondrin B |
| WO2010113984A1 (ja) | 2009-03-30 | 2010-10-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物 |
| BR112015029386B1 (pt) | 2013-06-26 | 2023-11-14 | Eisai R&D Management Co., Ltd. | Uso de eribulina e lenvatinibe como terapia de combinação e kit |
| ES2952680T3 (es) | 2016-04-28 | 2023-11-03 | Eisai R&D Man Co Ltd | Eribulina para inhibir el crecimiento tumoral |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2020097625A1 (en) * | 2018-11-09 | 2020-05-14 | G1 Therapeutics, Inc. | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| JP6141016B2 (ja) * | 2009-08-27 | 2017-06-07 | バイオノミックス リミテッド | 増殖性疾患の治療のための併用療法 |
| WO2012119077A1 (en) * | 2011-03-02 | 2012-09-07 | Morphotek Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| EP2833915A1 (en) * | 2012-04-02 | 2015-02-11 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
-
2015
- 2015-03-02 US US15/123,476 patent/US20170071903A1/en not_active Abandoned
- 2015-03-02 CN CN201580011593.4A patent/CN106029070A/zh active Pending
- 2015-03-02 RU RU2016136504A patent/RU2016136504A/ru unknown
- 2015-03-02 AU AU2015225436A patent/AU2015225436A1/en not_active Abandoned
- 2015-03-02 EP EP15758504.3A patent/EP3113775A4/en not_active Withdrawn
- 2015-03-02 JP JP2016555458A patent/JP2017507151A/ja active Pending
- 2015-03-02 SG SG11201607298QA patent/SG11201607298QA/en unknown
- 2015-03-02 WO PCT/US2015/018335 patent/WO2015134399A1/en active Application Filing
- 2015-03-02 CA CA2940983A patent/CA2940983A1/en not_active Abandoned
- 2015-03-02 KR KR1020167027369A patent/KR20160135230A/ko not_active Withdrawn
-
2016
- 2016-08-31 IL IL247586A patent/IL247586A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN106029070A (zh) | 2016-10-12 |
| US20170071903A1 (en) | 2017-03-16 |
| EP3113775A4 (en) | 2017-08-23 |
| CA2940983A1 (en) | 2015-09-11 |
| RU2016136504A3 (enrdf_load_stackoverflow) | 2018-10-25 |
| RU2016136504A (ru) | 2018-04-03 |
| KR20160135230A (ko) | 2016-11-25 |
| EP3113775A1 (en) | 2017-01-11 |
| IL247586A0 (en) | 2016-11-30 |
| AU2015225436A1 (en) | 2016-09-08 |
| WO2015134399A1 (en) | 2015-09-11 |
| JP2017507151A (ja) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| IL256333B (en) | Methods for the treatment of solid tumors using combined therapy with mtor inhibitor nanoparticles | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| IL310069B2 (en) | RAD1901 for use in cancer treatment | |
| IL256224B (en) | Combined therapy for cancer treatment | |
| LT3283527T (lt) | Kompleksinė terapija vėžio gydymui | |
| IL242386B (en) | Use of Aribolin and Lavetinib as a combination therapy for cancer treatment | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| PT3033086T (pt) | Terapia de combinação para o tratamento de cancro | |
| IL258521A (en) | Combination of treatments for cancer treatment | |
| IL248455B (en) | igf-1r antibody-drug conjugate and its use for cancer treatment | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| EP3226901A4 (en) | Combination therapy for treatment of cancer | |
| IL254842A0 (en) | Therapeutic preparations and methods for use in cancer treatment | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| EP3185884A4 (en) | Combination therapy for treatment of cancer | |
| IL258494A (en) | Rational combined therapy for cancer treatment | |
| IL252493A0 (en) | Compounds for use in the prevention or treatment of cancer | |
| HK1242990A1 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer | |
| ZA201403006B (en) | Composition for use in treatment of cancer | |
| GB201416605D0 (en) | Combination therapy to reduce the risk of and to treat cancer |